ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by the National Natural Science Foundation of China (82222038 and 81970259), the Outstanding Young Talents of National Defense Biotechnology (2023-JCJQ-ZQ-001 and 01-SWKJYCJJ06), and the Chongqing Science Fund for Distinguished Young Scholars (CSTB2022NSCQ-JQX0017).

All experimental procedures described in this article were approved by the Laboratory Animal Welfare and Ethics Committee of the Third Military Medical University (SCXK(PLA)20120031).
1. Experimental animals
<ol>
	<li>Use C57BL/6 mice, male, aged 8&#8211;10 weeks, weighing 23&#8211;28 g (Animal License No.: SCXK (Xiang) 2019-0004). House the mice in a specific pathogen-free (SPF) environment with free access to food and water. Maintain the housing conditions as follows: room temperature of (24 &#177; 2&#186;C), humidity of 50%&#8211;55%, and a 12 h/12 h light-dark cycle.</li>
</ol>
2. Bacterial preparation
<ol>
	<li>Use a suitable strain. Here, use Klebsiella pneumoniae American Type Culture Collection (ATCC) strain 43816.</li>
	<li>Prepare an appropriate culture medium (Luria-Bertani [LB] broth).</li>
	<li>Prepare bacteria for instillation.
	<ol>
		<li>Pick a single colony and inoculate it into 5 mL of LB broth, then incubate overnight (12 h) in a shaker at 37 &#176;C and 220 rpm.</li>
		<li>Transfer the overnight bacterial culture to fresh LB broth and culture for 3&#8211;4 h until reaching the high-density growth stage (optical density at 600 nm [OD600] &#8776; 0.8).</li>
		<li>After diluting the bacterial solution, take 100 &#181;L and add it to the bottom of the culture dish containing solid culture medium. Place it in a 37 &#176;C incubator for 12 h, count the number of colonies, and obtain the concentration of KP at 2 &#215; 109 CFU/mL, i.e., OD600 &#8776; 0.8.</li>
		<li>Adjust the concentration of the bacteria using 0.9% NaCl solution. Prepare three bacterial suspensions with concentrations of 1 &#215; 108 CFU/mL, 1 &#215; 106 CFU/mL, and 1 &#215; 104 CFU/mL for subsequent use.</li>
	</ol>
	</li>
</ol>
3. Intranasal instillation infection (Figure 1)
<ol>
	<li>Anesthetize the mouse via intraperitoneal injection of 2% sodium pentobarbital at a dose of 40 mg/kg (Figure 1A,B).</li>
	<li>When the mouse exhibits reduced consciousness but retains the swallowing reflex, aspirate 50 &#181;L of the bacterial suspension (or 0.9% NaCl solution as a control) using a micropipette.</li>
	<li>Gently hold the mouse&#39;s neck with the thumb placed on the front of the neck, and gently grasp the mouse&#39;s body with the rest of the fingers. Tilt the mouse&#39;s head backward (Figure 1C).</li>
	<li>Slowly instill the bacterial suspension into the mouse&#39;s nostrils using a pipette (approximately 5&#8211;10 &#181;L per drop). Instill one drop into one nostril at a time (Figure 1D).</li>
	<li>After observing that the mouse has inhaled the suspension, quickly lift the mouse upward and then slowly lower it to promote the inhalation of the suspension into the bronchi (Figure 1E,F).</li>
	<li>Switch to the other nostril and repeat the procedure. Drip alternately into both nostrils, 5-10&#160;&#181;L&#160;each time, until a total of 50&#160;&#181;L are inhaled.</li>
	<li>If the mouse coughs, sighs, or cannot inhale the bacterial solution during the operation, allow the mouse to rest and observe. After the situation stabilizes, continue the step of inhaling to ensure that the mouse inhales all the bacterial solution (or 0.9% NaCl).</li>
	<li>Fix the mouse in a supine position on a mouse board tilted at 60&#176; until consciousness is restored. Provide supplemental heat to facilitate anesthetic recovery; monitor animals continuously to prevent overheating. After the mouse recover from anesthesia, put them back&#160; return it to its cage with optimal temperature conditions, sufficient water, and food.</li>
</ol>
4. Model evaluation
NOTE: Four groups of mouse models were established via the aforementioned intranasal instillation method, namely the control group (group A, instilled with PBS), the 1 &#215; 104 KP concentration group (group B), the 1 &#215; 106&#160;KP concentration group (group C), and the 1 &#215; 108 KP concentration group (group D). Mouse were deeply anesthetized by intraperitoneal injection of 2% sodium pentobarbital (60 mg/kg). Adequate anesthetic depth was confirmed by the loss of righting reflex, toe-pinch withdrawal, and muscle relaxation prior to terminal cardiac puncture for model evaluation. Death was confirmed by cervical dislocation immediately following blood collection. The model was evaluated using the following methods:
<ol>
	<li>Evaluate the 12-h inflammatory indicators.
	<ol>
		<li>At 12 h after intranasal instillation of KP, collect blood (&#8805; 300 &#181;L) via cardiac puncture (n = 5 per group). Separate the serum by centrifugation (1000 &#215; g,10 min) and use it for the detection of cytokine interleukin-6 (IL-6).</li>
	</ol>
	</li>
	<li>24-h organ damage assessment
	<ol>
		<li>At 24 h after intranasal instillation of KP, collect blood (&#8805;300 &#181;L) via cardiac puncture (n = 5 per group),use the serum for biochemical indicator detection. Among these indicators, use alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to assess liver damage, creatine kinase (CK) for muscular damage, and blood urea nitrogen (BUN) for kidney damage.</li>
	</ol>
	</li>
	<li>Symptom assessment
	<ol>
		<li>Monitor the body weight of the mouse daily, and observe hair condition, activity level, and other parameters.</li>
	</ol>
	</li>
	<li>7-day cytokines and immune cells
	<ol>
		<li>At 7 days post-modeling (n = 10 [A/B], n = 15 [C], n = 40 [D]), collect blood via cardiac puncture for flow cytometry analysis to assess the percentages of lymphocytes, the proportion of major histocompatibility complex class II (MHC&#8209;II) expression in monocytes, the mean fluorescence intensity MFI) of IL-10 and TGF-&#946;1 in CD4+ T cells.</li>
		<li>Tissue processing
		<ol>
			<li>Mix blood samples (100 &#181;L) with red blood cell lysis buffer (300 &#181;L) at a volume ratio of 1:3. After 15 min of erythrocyte lysis at room temperature, centrifuge the mixture at 400 &#215; g for 5 min, and discard the supernatant.</li>
			<li>Resuspend the pellet in 200 &#181;L of red blood cell lysis buffer (volume ratio = 1:2) and incubate for 10 min for secondary lysis.</li>
			<li>Following another centrifugation at 400 &#215; g for 5 min, remove the supernatant, and resuspend the pellet in 100 &#181;L of cell stain buffer.</li>
			<li>Add 1 &#181;L of each flow cytometry antibody to the samples. Briefly, add CD45 for lymphocyte staining; CD45, CD116, Ly6G, Ly6C, and MHC-II antibodies for MHC&#8209;II detection; CD45, CD3, CD4, CD8, and CD25 antibodies for the measurement of IL&#8209;10 and TGF&#8209;&#946;1. The dilution ratio for each antibody listed above is 1:100.</li>
			<li>Incubate all samples at 4 &#176;C for 30 min in the dark. Thereafter, add 1 mL of cell stain buffer, then centrifuge at 400 &#215; g for 5 min; discard the supernatant.</li>
			<li>For the detection of lymphocytes and MHC-II, resuspend in 400 &#181;L of cell stain buffer prior to flow cytometry analysis.</li>
			<li>Subsequently, perform procedures for the detection of IL&#8209;10 and TGF&#8209;&#946;1 following steps 4.4.2.8&#8211;4.4.2.12:</li>
			<li>Add 1 mL of fixation buffer and incubate the samples at 4&#186;C in the dark for 60 min.</li>
			<li>After adding 1 mL of perm buffer, centrifuge the mixture at 400 &#215; g for 5 min, and discard the supernatant.</li>
			<li>Resuspend the cell pellet in 100 &#181;L of perm buffer, followed by the addition of 1 &#181;L each of Foxp3, IL-10, and TGF-&#946;1 antibodies. Incubate the samples at 4 &#176;C for 30 min in the dark.</li>
			<li>Next, add 1 mL of perm buffer, and centrifuge at 400 &#215; g for 5 min before removing the supernatant.</li>
			<li>Finally, resuspend the cells in 400 &#181;L of cell stain buffer and detect by flow cytometry.</li>
		</ol>
		</li>
		<li>Gating strategy
		<ol>
			<li>To detect lymphocytes, exclude debris and doublets on the FSC-A/FSC-H plot. Identify total leukocytes as CD45&#8314; events. Gate the lymphocytes based on low FSC/SSC within the CD45&#8314; population.</li>
			<li>To detect MHC-II, first gate leukocytes on FSC-A/SSC-A to exclude debris, followed by selection of CD45&#8314; cells. Identify myeloid cells as CD11b&#8314;, with neutrophils excluded by Ly6G negativity. Define classical monocytes as Ly6G&#8315; Ly6Chi cells, and assess MHC-II expression within this population.</li>
			<li>To detect IL-10 and TGF-&#946;1, exclude debris and doublets by FSC-A/SSC-A and FSC-A/FSC-H. Identify total T cells as CD45&#8314;CD3&#8314; events. Within the CD4&#8314;CD8&#8315; population, identify Tregs as CD25&#8314;FOXP3&#8314; cells. Quantify TGF-&#946;&#8314; cells in the Treg subset, and assess IL-10 expression across all CD4&#8314; T cells. Set all positive gates using FMO controls.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Bacterial count in bronchoalveolar lavage fluid (BALF) at 24 h after secondary infection
	<ol>
		<li>On day 7 after model establishment (n = 5 [A/B], n = 10 [C], n = 40 [D]), subject the mouse to intranasal instillation of 50 &#181;L of Pseudomonas aeruginosa (PA) (at a concentration of 6.8 &#215; 1010 CFU/mL) using the aforementioned intranasal instillation method.</li>
		<li>At 24 h after secondary infection with PA, collect 1.5 mL of bronchoalveolar lavage fluid (BALF). Serially dilute the BALF, plate it onto LB liquid medium, and incubate it in a constant-temperature incubator at 37 &#176;C for 24 h before colony counting.</li>
		<li>Follow these steps for BALF collection.
		<ol>
			<li>Euthanize the mouse (150 mg/kg 2% sodium pentobarbital) humanely, then place it supine with the neck hyperextended.</li>
			<li>Make a midline cervical incision to expose the trachea. Insert a blunt 24-G catheter into the trachea to just beyond the carina and secure it with a suture.</li>
			<li>Instill 0.5 mL sterile, ice-cold PBS into the lung via the tracheal cannula. Gently aspirate 3&#8211;5 times, recover the fluid, and repeat this lavage cycle 3 times for a total volume of approximately 1.5 mL.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Survival analysis
	<ol>
		<li>Use a separate cohort of mice for survival analysis (n = 10 [A/B/C], n = 40 [D]).</li>
		<li>Record the survival status of the mice within 7 days after infection.</li>
		<li>After secondary infection with PA, observe the mortality rate of the mice from day 7 to day 14.</li>
		<li>After observation, deeply anesthetize the mice with isoflurane (5%); anesthetic depth was confirmed by the loss of righting and toe-pinch reflexes, regular respiration, and muscle relaxation prior to euthanasia by intraperitoneal injection of an overdose of pentobarbital sodium (150 mg/kg), with death confirmed by cervical dislocation.</li>
	</ol>
	</li>
	<li>Statistical analysis
	<ol>
		<li>Perform normality tests and homogeneity of variance tests on the quantitative data.</li>
		<li>For comparisons between groups, use one-way analysis of variance (ANOVA) if the data are normally distributed and exhibit homogeneous variance; otherwise, use nonparametric tests.</li>
		<li>Perform survival analysis using the Kaplan-Meier method. Use the mixed-effects models to test differences in body weight changes between groups at different time points. Consider a p-value &#8804; 0.05 statistically significant.</li>
	</ol>
	</li>
</ol>

<ol><li>Singer, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+third+international+consensus+definitions+for+sepsis+and+septic+shock+%28sepsis-3%29%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">The third international consensus definitions for sepsis and septic shock (sepsis-3).</a> JAMA. 315 (8), 801-810 (2016).</li>
<li>Shankar-Hari, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Developing+a+new+definition+and+assessing+new+clinical+criteria+for+septic+shock%3A+for+the+third+international+consensus+definitions+for+sepsis+and+septic+shock+%28sepsis-3%29%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3).</a> JAMA. 315 (8), 775-787 (2016).</li>
<li>Seymour, C. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Assessment+of+clinical+criteria+for+sepsis%3A+for+the+third+international+consensus+definitions+for+sepsis+and+septic+shock+%28sepsis-3%29%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3).</a> JAMA. 315 (8), 762-774 (2016).</li>
<li>Meyer, N. J., Prescott, H. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sepsis+and+septic+shock%5BTitle%5D)+AND+%22N+Engl+J+Med%22%5BJournal%5D)">Sepsis and septic shock.</a> N Engl J Med. 391 (22), 2133-2146 (2024).</li>
<li>Kingsley, S. M., Bhat, B. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Differential+paradigms+in+animal+models+of+sepsis%5BTitle%5D)+AND+%22Curr+Infect+Dis+Rep%22%5BJournal%5D)">Differential paradigms in animal models of sepsis.</a> Curr Infect Dis Rep. 18 (9), 26(2016).</li>
<li>Hansen, V., Oren, E., Dennis, L. K., Brown, H. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Infectious+disease+mortality+trends+in+the+United+States%2C+1980-2014%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">Infectious disease mortality trends in the United States, 1980-2014.</a> JAMA. 316 (20), 2149-2151 (2016).</li>
<li>Ashurst, J. V., Dawson, A. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aAshurst%2C+JV+%22Klebsiella+pneumonia%22">Klebsiella pneumonia</a>. , StatPearls Publishing. Treasure Island, FL. (2025).</li>
<li>Jondle, C. N., Gupta, K., Mishra, B. B., Sharma, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Klebsiella+pneumoniae+infection+of+murine+neutrophils+impairs+their+efferocytic+clearance+by+modulating+cell+death+machinery%5BTitle%5D)+AND+%22PLoS+Pathog%22%5BJournal%5D)">Klebsiella pneumoniae infection of murine neutrophils impairs their efferocytic clearance by modulating cell death machinery.</a> PLoS Pathog. 14 (10), e1007338(2018).</li>
<li>Aghamohammad, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((First+report+of+extended-spectrum+betalactamase-producing+Klebsiella+pneumoniae+among+fecal+carriage+in+Iran%3A+high+diversity+of+clonal+relatedness+and+virulence+factor+profiles%5BTitle%5D)+AND+%22Microb+Drug+Resist%22%5BJournal%5D)">First report of extended-spectrum betalactamase-producing Klebsiella pneumoniae among fecal carriage in Iran: high diversity of clonal relatedness and virulence factor profiles.</a> Microb Drug Resist. 26 (3), 261-269 (2020).</li>
<li>Bengoechea, J. A., Sa Pessoa, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Klebsiella+pneumoniae+infection+biology%3A+living+to+counteract+host+defenses%5BTitle%5D)+AND+%22FEMS+Microbiol+Rev%22%5BJournal%5D)">Klebsiella pneumoniae infection biology: living to counteract host defenses.</a> FEMS Microbiol Rev. 43 (2), 123-144 (2019).</li>
<li>Assoni, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Animal+models+of+Klebsiella+pneumoniae+mucosal+infections%5BTitle%5D)+AND+%22Front+Microbiol%22%5BJournal%5D)">Animal models of Klebsiella pneumoniae mucosal infections.</a> Front Microbiol. 15, 1367422(2024).</li>
<li>Hotchkiss, R. S., Monneret, G., Payen, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sepsis-induced+immunosuppression%3A+from+cellular+dysfunctions+to+immunotherapy%5BTitle%5D)+AND+%22Nat+Rev+Immunol%22%5BJournal%5D)">Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.</a> Nat Rev Immunol. 13 (12), 862-874 (2013).</li>
<li>Van Der Poll, T., Van De Veerdonk, F. L., Scicluna, B. P., Netea, M. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+immunopathology+of+sepsis+and+potential+therapeutic+targets%5BTitle%5D)+AND+%22Nat+Rev+Immunol%22%5BJournal%5D)">The immunopathology of sepsis and potential therapeutic targets.</a> Nat Rev Immunol. 17 (7), 407-420 (2017).</li>
<li>Diboue Betote, P. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sex-dependent+vulnerability+for+Wistar+rats+model+following+intranasal+instillation+with+Klebsiella+pneumoniae+ATCC+43816+causing+lobar+pneumonia%5BTitle%5D)+AND+%22Pneumonia%22%5BJournal%5D)">Sex-dependent vulnerability for Wistar rats model following intranasal instillation with Klebsiella pneumoniae ATCC 43816 causing lobar pneumonia.</a> Pneumonia. 16 (1), 5(2024).</li>
<li>Leus, I. V., Zgurskaya, H. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((No+two+are+alike%3A+on+the+role+of+Klebsiella+pneumoniae+permeability+barriers+in+antibiotic+susceptibility+and+persistence%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">No two are alike: on the role of Klebsiella pneumoniae permeability barriers in antibiotic susceptibility and persistence.</a> Antimicrob Agents Chemother. 69 (8), e0008525(2025).</li>
<li>Siempos, I. I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cecal+ligation+and+puncture-induced+sepsis+as+a+model+to+study+autophagy+in+mice%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Cecal ligation and puncture-induced sepsis as a model to study autophagy in mice.</a> J Vis Exp. (84), e51066(2014).</li>
<li>Vincent, J. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((International+study+of+the+prevalence+and+outcomes+of+infection+in+intensive+care+units%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">International study of the prevalence and outcomes of infection in intensive care units.</a> JAMA. 302 (21), 2323-2329 (2009).</li>
<li>Prescott, H. C., Angus, D. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enhancing+recovery+from+sepsis%3A+a+review%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">Enhancing recovery from sepsis: a review.</a> JAMA. 319 (1), 62-75 (2018).</li>
<li>Barichello, T., Generoso, J. S., Singer, M., Dal-Pizzol, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Biomarkers+for+sepsis%3A+more+than+just+fever+and+leukocytosis-a+narrative+review%5BTitle%5D)+AND+%22Crit+Care%22%5BJournal%5D)">Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review.</a> Crit Care. 26 (1), 14(2022).</li>
<li>Vulliamy, P. E., Perkins, Z. B., Brohi, K., Manson, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Persistent+lymphopenia+is+an+independent+predictor+of+mortality+in+critically+ill+emergency+general+surgical+patients%5BTitle%5D)+AND+%22Eur+J+Trauma+Emerg+Surg%22%5BJournal%5D)">Persistent lymphopenia is an independent predictor of mortality in critically ill emergency general surgical patients.</a> Eur J Trauma Emerg Surg. 42 (6), 755-760 (2016).</li>
<li>Pei, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Expert+consensus+on+the+monitoring+and+treatment+of+sepsis-induced+immunosuppression%5BTitle%5D)+AND+%22Mil+Med+Res%22%5BJournal%5D)">Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression.</a> Mil Med Res. 9 (1), 74(2022).</li>
<li>Lang, J. D., Matute-Bello, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lymphocytes%2C+apoptosis+and+sepsis%3A+making+the+jump+from+mice+to+humans%5BTitle%5D)+AND+%22Crit+Care%22%5BJournal%5D)">Lymphocytes, apoptosis and sepsis: making the jump from mice to humans.</a> Crit Care. 13 (1), 109(2009).</li>
<li>Wu, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Predictive+value+of+the+neutrophil-to-lymphocyte+ratio+in+the+prognosis+and+risk+of+death+for+adult+sepsis+patients%3A+a+meta-analysis%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Predictive value of the neutrophil-to-lymphocyte ratio in the prognosis and risk of death for adult sepsis patients: a meta-analysis.</a> Front Immunol. 15, 1336456(2024).</li>
<li>Siegler, B. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Postoperative+abdominal+sepsis+induces+selective+and+persistent+changes+in+CTCF+binding+within+the+MHC-II+region+of+human+monocytes%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Postoperative abdominal sepsis induces selective and persistent changes in CTCF binding within the MHC-II region of human monocytes.</a> PLoS One. 16 (5), e0250818(2021).</li>
<li>Pachot, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Messenger+RNA+expression+of+major+histocompatibility+complex+class+II+genes+in+whole+blood+from+septic+shock+patients%5BTitle%5D)+AND+%22Crit+Care+Med%22%5BJournal%5D)">Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients.</a> Crit Care Med. 33 (1), 31-38 (2005).</li>
<li>Padovani, C. M., Yin, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunosuppression+in+sepsis%3A+biomarkers+and+specialized+pro-resolving+mediators%5BTitle%5D)+AND+%22Biomedicines%22%5BJournal%5D)">Immunosuppression in sepsis: biomarkers and specialized pro-resolving mediators.</a> Biomedicines. 12 (1), 175(2024).</li>
<li>Misra, A. K., Levy, M. M., Ward, N. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Biomarkers+of+immunosuppression%5BTitle%5D)+AND+%22Crit+Care+Clin%22%5BJournal%5D)">Biomarkers of immunosuppression.</a> Crit Care Clin. 36 (1), 167-176 (2020).</li>
<li>Monneret, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+anti-inflammatory+response+dominates+after+septic+shock%3A+association+of+low+monocyte+HLA-DR+expression+and+high+interleukin-10+concentration%5BTitle%5D)+AND+%22Immunol+Lett%22%5BJournal%5D)">The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration.</a> Immunol Lett. 95 (2), 193-198 (2004).</li>
<li>Bergmann, C. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Potential+targets+to+mitigate+trauma-+or+sepsis-induced+immune+suppression%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Potential targets to mitigate trauma- or sepsis-induced immune suppression.</a> Front Immunol. 12, 622601(2021).</li>
<li>Van Vught, L. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Incidence%2C+risk+factors%2C+and+attributable+mortality+of+secondary+infections+in+the+intensive+care+unit+after+admission+for+sepsis%5BTitle%5D)+AND+%22JAMA%22%5BJournal%5D)">Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis.</a> JAMA. 315 (14), 1469-1479 (2016).</li>
<li>Jones-Nelson, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+neutrophilic+response+to+Pseudomonas+damages+the+airway+barrier%2C+promoting+infection+by+Klebsiella+pneumoniae%5BTitle%5D)+AND+%22Am+J+Respir+Cell+Mol+Biol%22%5BJournal%5D)">The neutrophilic response to Pseudomonas damages the airway barrier, promoting infection by Klebsiella pneumoniae.</a> Am J Respir Cell Mol Biol. 59 (6), 745-756 (2018).</li>
</ol>

The authors declare no conflict of interest.

Sepsis is a complex clinical syndrome, and the characteristic immunosuppressive state during its late stage is a key factor leading to patient death12,13. Therefore, preclinical models that accurately simulate the pathophysiology of sepsis-induced immunosuppression are crucial for in-depth exploration of its mechanisms and the development of new therapies. In this study, we successfully established and validated a mouse sepsis model induced by intranasal instilla...

Sepsis is a life-threatening organ failure resulting from the host&#39;s inappropriate response to infection1,2,3. It is one of the leading causes of death in intensive care units (ICUs). Globally, there are 48.9 million sepsis cases annually, with 11 million associated deaths4. Despite recent advancements in anti-infective therapy and organ support technologies, the pathogenesis of sepsis remains incompletely understood, and specific treatment options are lacking. As such, sepsis has become a key focus and challenge in clinical medical research4.
Animal models play an irreplaceable role in basic and translational medical research, serving as essential tools for investigating sepsis pathogenesis and evaluating novel therapeutic strategies. By simulating the pathophysiological processes of human sepsis, these models not only facilitate exploration of key mechanisms such as immune disorders and organ dysfunction but also provide an experimental platform for drug screening and the development of intervention strategies. Among various animal models, mice are the most commonly used in sepsis research due to their well-defined genetic background, extensive research on their immune system, and ease of manipulation.
Currently, several sepsis animal models based on different paradigms are available, including endotoxin models, bacterial infusion models, cecal ligation and puncture (CLP) models, and colon ascendens stent peritonitis (CASP) models5. However, these models lack natural infection routes, making it challenging to truly reflect the clinical infection process. Studies have reported that pneumonia is the primary cause of sepsis in the United States6. Therefore, establishing a mouse sepsis model that mimics natural infection routes, exhibits immunosuppressive features, and is easy to operate with high reproducibility is of great significance for in-depth research into the immune mechanisms of sepsis and for evaluating potential intervention strategies.
Klebsiella pneumoniae (KP) accounts for 3% to 8% of all hospital-acquired bacterial infections7,8,9. This bacterium can enter the body through various portals, including the respiratory, gastrointestinal, and urinary tracts, as well as skin, and infections caused by KP have a poor prognosis, especially in immunocompromised patients7,10. Given that pneumonia is the leading cause of sepsis and KP is a common respiratory pathogen associated with poor outcomes, KP is an ideal candidate for establishing a clinically relevant sepsis model.
Although a variety of animal models of KP infection, including the intranasal method, have been established previously11, only a few studies have focused on optimizing the model to induce sepsis-associated immunosuppression or defining the optimal KP concentration for model establishment. This gap limits the utility of existing KP models for studying sepsis-induced immune dysfunction.
To address this need, we established a sepsis-induced immunosuppression model in mice via intranasal instillation of KP. Compared to existing models, this model simulates the natural pathways of respiratory infections. The model was further validated to provide a method for subsequent research.

<table><tbody><tr><td>Biochemical incubator</td><td>YSEI</td><td>SHH-150L</td><td>Bacterial incubation</td></tr><tr><td>C57BL/6J mice</td><td>Vital River Laboratories</td><td>8-10 weeks, male</td><td></td></tr><tr><td>CD116b</td><td>BioLegend</td><td>101257</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>CD25</td><td>BD bioscience</td><td>740447</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>CD3</td><td>BioLegend</td><td>100203</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>CD4</td><td>BioLegend</td><td>100544</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>CD45</td><td>BioLegend</td><td>103116</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>CD8</td><td>BioLegend</td><td>100752</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>Cell stain buffer&amp;nbsp;</td><td>BioLegend</td><td>420201</td><td></td></tr><tr><td>Constant temperature shaker</td><td>Honour</td><td>HNY-100B</td><td>Bacterial cultivation</td></tr><tr><td>Flow cytometer</td><td>Beckman Coulter</td><td>CytoFLEX</td><td>Flow cytometry analysis</td></tr><tr><td>High-speed centrifuge</td><td>Beckman Coulter</td><td>AIIEGRA</td><td></td></tr><tr><td>IDEXX catalyst one</td><td>IDEXX</td><td>Catalyst One</td><td>Biochemical analysis</td></tr><tr><td>IL-10</td><td>BioLegend</td><td>505026</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>Insulin cyringe&amp;nbsp;</td><td>WEGO</td><td>1mL</td><td>Blood collection</td></tr><tr><td>Klebsiella pneumoniae ATCC 43816</td><td>biobw.org</td><td>bio-81659</td><td></td></tr><tr><td>LB Broth (powder)</td><td>Solarbio</td><td>L1010</td><td>LB liquid culture medium</td></tr><tr><td>LB Broth (powder)</td><td>Solarbio</td><td>L1015</td><td>LB agar plate</td></tr><tr><td>LY6C</td><td>BioLegend</td><td>128010</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>Ly6G</td><td>BioLegend</td><td>127606</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>MHC-II</td><td>BioLegend</td><td>107622</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>Micropipette</td><td>Eppendorf</td><td>P100</td><td></td></tr><tr><td>Red blood cell lysis buffer</td><td>Solarbio</td><td>R1010</td><td></td></tr><tr><td>Spectrophotometer</td><td>Eppendorf</td><td>Eppendorf6131</td><td>Optical density measurement</td></tr><tr><td>Statistical software</td><td>GraphPad Software</td><td>Graphpad Prism10.0</td><td></td></tr><tr><td>Sterile and enzyme-free pipette tips</td><td>Biosharp</td><td>200&amp;mu;L</td><td></td></tr><tr><td>TF diluent buffer</td><td>BD Pharmingen</td><td>51-90008101</td><td></td></tr><tr><td>TF fix/perm buffer</td><td>BD Pharmingen</td><td>51-90008100</td><td></td></tr><tr><td>TF perm/wash buffer</td><td>BD Pharmingen</td><td>51-90008102</td><td></td></tr><tr><td>TGF-&amp;beta;1</td><td>BioLegend</td><td>141406</td><td>Flow Antibodies (Anti-Mouse)</td></tr><tr><td>Varioskan LUX multimodemicroplate reader</td><td>Thermo Scientific</td><td>Varioskan LUX&amp;nbsp;</td><td></td></tr></tbody></table>

establishment of a mouse sepsis-induced immunosuppression model by intranasal instillation of bacteria

Establishment of A Mouse Sepsis-Induced Immunosuppression Model By Intranasal Instillation of Bacteria

Sepsis is a life-threatening organ failure caused by the host&#39;s inappropriate response to infection. Pneumonia is the primary cause of sepsis. Animal models are important tools for studying the pathogenesis of sepsis and evaluating new treatment strategies. Previous animal models of sepsis lacked natural infection pathways, making it difficult to accurately reflect the clinical infection process.
This study introduced a mouse sepsis immunosuppression model established by intranasal instillation of Klebsiella pneumoniae (KP) to simulate the natural respiratory infection pathway. After modeling with different concentrations of KP, the inflammation of the model was evaluated at 12 h for cytokine interleukin-6 (IL-6) levels, and organ damage was evaluated at 24 h for alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), and blood urea nitrogen (BUN) levels. The survival rate of the model was analyzed after 7 days. The percentage of lymphocytes and white blood cells, the proportion of major histocompatibility complex class II (MHC-II) expression in monocytes, and the mean fluorescence intensity (MFI) of IL-10 and TGF-&#946;1 in CD4+ T cells were observed to evaluate the immune suppression in mice. After 7 days of modeling, a secondary infection was performed by intranasal instillation of Pseudomonas aeruginosa (PA). The bacterial load in bronchoalveolar lavage fluid (BALF) 24 h after secondary infection and the mortality rate within 14 days were assessed to further evaluate the model&#39;s immune suppression.
Nasal instillation of high-concentration Klebsiella pneumoniae can effectively induce an immune suppression. Its purpose is to simulate sepsis induced by a natural respiratory infection pathway and to provide a standard model for sepsis research in animals.

At 12 h after intranasal instillation, the serum IL-6 level in the 1 &#215; 108 KP group was significantly increased (p &#60; 0.0001, n = 5) (Figure 2A). At 24 h after intranasal instillation, the serum levels of ALT (p &#60; 0.01, n = 5) (Figure 2B), AST (p &#60; 0.01, n = 5) (Figure 2C), CK (p &#60; 0.01, n = 5) (Figure 2D), and BUN (p &#60; 0.001, n = 5) (Figure 2E</st...

Here, we present a protocol for establishing a mouse sepsis immunosuppression model via intranasal instillation of Klebsiella pneumoniae and validated the model through various indicators.

Sepsis is a life-threatening organ failure caused by the host&#39;s inappropriate response to infection. Pneumonia is the primary cause of sepsis. Animal ...

establishment-mouse-sepsis-induced-immunosuppression-model-intranasal

Research

JoVE Journal

Immunology and Infection

We illustrate non-surgical delivery of test materials into the lungs of anesthetized mice via the trachea. This method permits lung exposure to bacterial and viral pathogens, cytokines, antibodies, beads, chemicals, or dyes. We further describe harvesting and processing of lungs and lung draining lymph nodes (LDLNs) for flow cytometry.

Non-surgical Intratracheal Instillation of Mice with Analysis of Lungs and Lung Draining Lymph Nodes by Flow Cytometry

Colonization of the murine nasopharynx with Streptococcus pneumoniae and the subsequent extraction of adherent or recruited cells is described. This technique involves flushing the nasopharynx and collection of the fluid through the nares and is adaptable for various readouts, including differential cell quantification and analysis of mRNA expression in situ.

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Using optimized human peripheral blood mononuclear cell (PBMC) ex vivo assays, we showed that a combustible tobacco product preparation markedly suppresses receptor-mediated intracellularly secreted cytokines and cytolytic ability of effector PBMCs. These rapid assays may be useful in product evaluation and understanding the potential long-term effects of tobacco exposure.

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

There is an overall lack of knowledge about how vaccines work. Here we propose the combined use of reverse genetics and bone marrow chimeric mice to gain insight into the early host immune responses to vaccines with a special focus on dendritic cells and T cell immunity.

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

This article presents two protocols: one to measure anaerobic bacteria that can successfully invade and survive within the host, and the other to visualize anaerobic bacteria interacting with host cells. This study can be applied to any cultivable anaerobe and any eukaryotic cell type.

Porphyromonas gingivalis as a Model Organism for Assessing Interaction of Anaerobic Bacteria with Host Cells

A method is described herein for the determination of inter-Kingdom association and competition (bacterial and fungal) for adherence to virus-infected HeLa cell monolayers. This protocol can be extended to multiple combinations of prokaryotes, eukaryotes, and viruses.

Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi

This protocol outlines the cefoperazone mouse model of Clostridium difficile infection (CDI) using a clinically-relevant and genetically-tractable strain, R20291. Emphasis on clinical disease monitoring, C. difficile bacterial enumeration, toxin cytotoxicity, and histopathological changes throughout CDI in a mouse model are detailed in the protocol.

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Transurethral instillation is a challenging procedure and has not been well described in the literature. The aim of this manuscript is to describe a technique for transurethral insertion of a catheter for intravesical delivery of liquids with active substances into the urinary bladder and/or prostate in adult male mice.

Transurethral Instillation Procedure in Adult Male Mouse

This protocol provides a reliable method to establish humanized mice with both human immune system and liver cells. Dual reconstituted immunodeficient mice achieved via intrasplenic injection of human hepatocytes and CD34+ hematopoietic stem cells are susceptible to human immunodeficiency virus-1 infection and recapitulate liver damage as observed in HIV-infected patients.

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Here we present an effective method to investigate the antifibrotic activity of intravenously infused human mesenchymal stromal cells obtained from the whole umbilical cord following the induction of lung injury by an endotracheal injection of bleomycin in C57BL/6 mice. This protocol can be easily extended to the preclinical testing of other therapeutics.

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Army Medical University.  Here, we present a protocol for establishing a mouse sepsis immunosuppression model via intranasal instillation of Klebsiella pneumoniae and validated the model through various indicators.

Establishment of A Mouse Sepsis-Induced Immunosuppression Model By Intranasal Instillation of Bacteria

Explore More Videos